{"product_id":"cergutuzumab-elisa-kit","title":"Cergutuzumab ELISA Kit","description":"\u003cp\u003e\u003cb\u003eSize\u003c\/b\u003e:96T\u003c\/p\u003e\u003cp\u003e\u003cb\u003eApplications\u003c\/b\u003e:ELISA\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAccession\u003c\/b\u003e:P06731\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStability and Storage\u003c\/b\u003e:The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDetection method\u003c\/b\u003e:Colorimetric\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSample type\u003c\/b\u003e:Plasma, Serum\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay type\u003c\/b\u003e:Quantitative\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSensitivity\u003c\/b\u003e:0.156 μg\/ml\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRange\u003c\/b\u003e:0.31-5 μg\/mL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRecovery\u003c\/b\u003e:80-120%\u003c\/p\u003e\u003cp\u003e\u003cb\u003eProperties\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExperimental Procedure\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eBackground\u003c\/b\u003e:cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-mediated effector functions. Its molecular design aims to (i) avoid preferential activation of regulatory T-cells vs. immune effector cells by removing CD25 binding; (ii) increase the therapeutic index of IL-2 therapy by (a) preferential retention at the tumor by having a lower dissociation rate from CEA-expressing cancer cells vs. IL-2R-expressing cells, (b) avoiding any FcγR-binding and Fc effector functions and (c) reduced binding to endothelial cells expressing CD25; and (iii) improve the pharmacokinetics, and thus convenience of administration, of IL-2.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAlternative Names\u003c\/b\u003e:CEA-IL-2v, RG7813, RO-6895882, 1509916-03-3\u003c\/p\u003e\u003cp\u003e\u003cb\u003eShipping\u003c\/b\u003e:2-8 ℃\u003c\/p\u003e\u003cp\u003e\u003cb\u003eNote\u003c\/b\u003e:For Research Use Only.\u003c\/p\u003e","brand":"GeneBio Systems","offers":[{"title":"Default Title","offer_id":48655942287460,"sku":"DY546018","price":764.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0558\/8588\/9636\/files\/no_image_default_image-jpeg_750d6f4d-0e72-47e4-a94a-0f2d65222f3a.jpg?v=1782808765","url":"https:\/\/www.genebiosystems.com\/en-fr\/products\/cergutuzumab-elisa-kit","provider":"GeneBio ","version":"1.0","type":"link"}